Stock Market Today: Another Vaccine-Trial Stumble Clips Wall Street's Optimism
Johnson & Johnson (JNJ) paused a vaccine study, and Eli Lilly (LLY) was forced to do the same on a treatment trial, hampering stocks Tuesday.
Investors had plenty to chew on Tuesday, and it showed in a down day for stocks.
The big headline out of the gate was Johnson & Johnson (JNJ, -2.3%) pausing late-stage trials for its promising COVID-19 vaccine due to an "unexplained illness," which, as we explained when AstraZeneca (AZN) was forced to do the same, isn't uncommon and doesn't necessarily spell doom for the treatment.
"JNJ decided to temporarily halt all dosing of the Covid-19 vaccine candidate due to an unexplained illness in a volunteer in the study," writes CFRA's Sel Hardy, who nonetheless maintained a Strong Buy rating on JNJ and upgraded earnings estimates after the company's strong third-quarter earnings results. "We welcome JNJ's transparency and expect to see further clarity as the issue is examined by an independent board."
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Meanwhile, stimulus talks remained muddy; Senate Majority Leader Mitch McConnell said his chamber would vote on a bill centered around the Paycheck Protection Program (PPP) sometime this month, though it's uncertain whether it would get past the House.
Apple (AAPL, -2.7%) gave up a little of its recent gains after it unveiled a suite of four new iPhones, including an iPhone 12 Mini with a 5.4-inch screen. And JPMorgan Chase (JPM, -1.6%), which kicked off the Q3 earnings calendar by beating expectations, still slumped as CEO Jamie Dimon warned more stimulus is needed to help the economy.
The Dow Jones Industrial Average slipped 0.6% to 28,679.
Other action in the stock market today:
- The Nasdaq Composite managed a mere 0.1% decline to 11,863.
- The S&P 500 fell 0.6% to 3,511.
- The small-cap Russell 2000 lost 0.7% to 1,636.
COVID Treatments' Push and Pull on Wall Street
The broader market results don't indicate much fallout from today's disappointing COVID-19 news, which also included a halt to Eli Lilly's (LLY, -2.9%) antibody treatment.
But take a closer look: Industrials, real estate, banks and energy, which rely heavily on robust economic activity, were solidly lower today. However, technology and communications once again showed relative strength as they have all year, bolstering the fortunes of technology funds such as these 15 products, and that should continue to be the case as long as effective treatments and vaccines remain elusive.
The same goes for the Invesco QQQ Trust (QQQ), which invests in the index composed of the Nasdaq's 100 largest financials and has raked in billions in assets this year, prompting Invesco to launch even more funds tied to the index. (You can read about a host of Nasdaq-100 products here.)
At some point, however, a vaccine or treatment will finally get the green light, and while it might take months to reach most of America's population, most experts expect that to "flip the switch" for a host of battered industries. Here, we look at 11 stocks to buy that are in rough shape right now, but that could pivot in a heartbeat when a game-changing medical breakthrough is announced.
Kyle Woodley was long AAPL and QQQ as of this writing.
-
Stocks Chop as the Unemployment Rate Jumps: Stock Market TodayNovember job growth was stronger than expected, but sharp losses in October and a rising unemployment rate are worrying market participants.
-
Should You Renew Your CD?With rate cuts impacting earnings, we examine if now is a wise time to renew CDs.
-
7 Ways to Plan Now to Save on Medicare IRMAA Surcharges LaterUnderstand the critical two-year lookback period and why aggressive planning before you enroll in Medicare is the most effective way to minimize IRMAA.
-
Stocks Struggle Ahead of November Jobs Report: Stock Market TodayOracle and Broadcom continued to fall, while market participants looked ahead to Tuesday's jobs report.
-
Dow Rises 497 Points on December Rate Cut: Stock Market TodayThe basic questions for market participants and policymakers remain the same after a widely expected Fed rate cut.
-
JPMorgan's Drop Drags on the Dow: Stock Market TodaySmall-cap stocks outperformed Tuesday on expectations that the Fed will cut interest rates on Wednesday.
-
Crypto Trends to Watch in 2026Cryptocurrency is still less than 20 years old, but it remains a fast-moving (and also maturing) market. Here are the crypto trends to watch for in 2026.
-
Dow Slides 427 Points to Open December: Stock Market TodayThe final month of 2025 begins on a negative note after stocks ended November with a startling rally.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
-
Stocks Extend Win Streak on Black Friday: Stock Market TodayThe main indexes notched wins in Friday's shortened session, with the blue-chip Dow Jones Industrial Average closing higher on the month.
